Avacta Group (AIM:AVCT), the AIM-listed oncology drug developer, said its lead next-generation pre|CISION drug candidate AVA6103 has achieved clinical proof of mechanism in the ongoing Phase 1 FOCUS-01 trial.
The readout matters because it links preclinical modelling directly to patient data, the gap that typically determines whether a drug platform's promise survives contact with the clinic.
Across the first three dose levels, tested in 19 patients, AVA6103 showed a clean safety profile even at a payload dose 50% above the maximum tolerated dose of conventional exatecan, the chemotherapy agent the platform is designed to deliver.
Neutropenia occurred in none of the AVA6103 patients, against 22% on comparable doses of Enhertu and 64% at the equivalent dose of conventional exatecan.
Pharmacokinetic data matched preclinical predictions closely, with controlled release of exatecan detectable in patients for days after dosing, consistent with the drug being retained in a tumour "reservoir" as designed.
A separate preclinical head-to-head study in a HER2-positive, FAP-positive gastric cancer model found AVA6103 produced deep, prolonged partial responses in all six treated animals, against a mixed response for Enhertu.
"These clinical findings provide a gateway for Avacta to link multiple payloads and access previously unaddressable markets", said chief executive Christina Coughlin, adding that the data "greatly increase our partnering position across the Next Gen platform".
The trial continues to enrol patients into two dosing arms, with first efficacy data, including tumour biopsy results, expected in the first half of 2027.
News Intelligence what this means for the company
Avacta's AVA6103 has cleared a critical clinical hurdle: proof that its drug-release mechanism works in patients as preclinical models predicted, with a clean safety profile across 19 patients that outperforms both conventional chemotherapy and the marketed comparator Enhertu on neutropenia. This bridges the gap between bench and bedside that typically determines whether a platform survives first-in-human testing, and the CEO explicitly flagged it as a catalyst for partnership discussions—material for a clinical-stage company whose cash runway extended only to early Q1 2027 in June.
The proof-of-mechanism readout validates the platform's core hypothesis and removes a major binary risk before efficacy data arrive in H1 2027. For a pre-revenue biotech, this shifts the narrative from 'will it work in humans?' to 'how big is the opportunity?'—a meaningful step toward de-risking the path to partnership or value inflection, though efficacy and commercial viability remain unproven.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
